<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639844</url>
  </required_header>
  <id_info>
    <org_study_id>BP-C-004</org_study_id>
    <nct_id>NCT03639844</nct_id>
  </id_info>
  <brief_title>BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study</brief_title>
  <official_title>Expanded Access Protocol for CaspaCIDe T Cells From An HLA-Partially Matched Related Donor After Negative Selection of TCR αβ+T Cells In Pediatric Patients Affected by Hematological and Other Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellicum Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellicum Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Providing access of BPX-501 gene modified T cells and rimiducid to pediatric patients who do&#xD;
      not meet the eligibility criteria of the BP-U-004 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an expanded access protocol of BPX-501 T cells infused after T cell-depleted HSCT in&#xD;
      pediatric patients with non-malignant hematologic disorders eligible for treatment on the&#xD;
      BP-U-004 study.&#xD;
&#xD;
      The purpose of this protocol is to provide access to the CaspaCIDe system combination product&#xD;
      (BPX-501 gene modified T cells and rimiducid) to patients on a case by case basis who do not&#xD;
      meet the BP-U-004 protocol eligibility criteria. BPX-501 infusion can enhance immune&#xD;
      reconstitution with the potential for reducing the severity and duration of severe acute&#xD;
      GVHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Hurler Syndrome</condition>
  <condition>Inherited Metabolic Disorder</condition>
  <condition>Lysosomal Storage Disorder</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <condition>Inborn Errors of Metabolism</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rivogenlecleucel</intervention_name>
    <description>BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.</description>
    <other_name>BPX-501 T cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rimiducid</intervention_name>
    <description>Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD</description>
    <other_name>AP1903</other_name>
    <other_name>Rimiducid for Injection</other_name>
    <other_name>AP1903 for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females&#xD;
&#xD;
          2. Age &lt; 21 years and &gt; 3 months&#xD;
&#xD;
          3. Life expectancy &gt; 10 weeks&#xD;
&#xD;
          4. Patients deemed eligible for allogeneic stem cell transplantation.&#xD;
&#xD;
          5. Non-malignant disorders including:&#xD;
&#xD;
               1. inherited metabolic disorders such as adrenal leukodystrophy;&#xD;
&#xD;
               2. lysosomal storage disorders such as Hurler syndrome or metachromatic&#xD;
                  leukodystrophy&#xD;
&#xD;
               3. other inborn errors of metabolism&#xD;
&#xD;
          6. Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically&#xD;
             identical relative evaluated using high resolution molecular typing).&#xD;
&#xD;
          7. A minimum genotypic identical match of 5/10 is required.&#xD;
&#xD;
          8. The donor and recipient must be identical, as determined by high resolution typing, at&#xD;
             least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, and HLA-&#xD;
             DRB1.&#xD;
&#xD;
          9. Lansky/Karnofsky score &gt; 50&#xD;
&#xD;
         10. Signed written informed consent&#xD;
&#xD;
        3.2 Subject exclusion criteria&#xD;
&#xD;
          1. Age &lt; 3 months or &gt;21 years&#xD;
&#xD;
          2. Patients with non-malignant disorders eligible for treatment on the BP-U-004 study:&#xD;
&#xD;
               1. primary immune deficiencies,&#xD;
&#xD;
               2. severe aplastic anemia not responding to immune suppressive therapy,&#xD;
&#xD;
               3. osteopetrosis,&#xD;
&#xD;
               4. selected cases of hemoglobinopathies and&#xD;
&#xD;
               5. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal&#xD;
                  malignant evolution (MDS, AML)&#xD;
&#xD;
          3. Greater than Grade II acute GVHD or chronic extensive GVHD due to a previous allograft&#xD;
             at the time of inclusion&#xD;
&#xD;
          4. Patient receiving an immunosuppressive treatment for GVHD treatment due to a previous&#xD;
             allograft at the time of inclusion&#xD;
&#xD;
          5. Dysfunction of liver (ALT/AST &gt; 5 times normal value, or bilirubin &gt; 3 times normal&#xD;
             value), or of renal function (creatinine clearance &lt; 30 ml / min)&#xD;
&#xD;
          6. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive&#xD;
             heart failure or left ventricular ejection fraction &lt; 40%)&#xD;
&#xD;
          7. Current active infectious disease (including positive HIV serology or viral RNA)&#xD;
&#xD;
          8. Serious concurrent uncontrolled medical disorder&#xD;
&#xD;
          9. Pregnant or breast feeding female patient&#xD;
&#xD;
         10. Lack of parents'/guardian's informed consent.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bellicum Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Bellicum Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University; Division of Pediatric Stem Cell Transplant &amp; Regenerative Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

